Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma
Clinical trial NCT03468153 · UNKNOWN
Trial details
- NCT number
- NCT03468153
- Sponsor
- Ruijin Hospital
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-01-01
- Primary completion
- 2019-01-01
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.